These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17139369)

  • 1. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
    Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
    Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of dalteparin during haemodialysis.
    Nigten J; de Groot KA; Grootendorst DC; Koolen SL; Herruer MH; Schut NH
    Nephron Clin Pract; 2013; 124(3-4):179-83. PubMed ID: 24401673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.
    Rommers MK; Van der Lely N; Egberts TC; van den Bemt PM
    Crit Care; 2006; 10(3):R93. PubMed ID: 16790078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study.
    Kani C; Markantonis SL; Nicolaou C; Maggina N
    J Crit Care; 2006 Mar; 21(1):79-84. PubMed ID: 16616629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalteparin dosing in high-flux haemodialysis and haemodiafiltration.
    Sridharan S; Berdeprado J; Sivalingam M; Farrington K
    Nephron Clin Pract; 2012; 122(1-2):53-7. PubMed ID: 23548465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin.
    Sagedal S; Hartmann A; Osnes K; Bjørnsen S; Torremocha J; Fauchald P; Kofstad J; Brosstad F
    Nephrol Dial Transplant; 2006 Feb; 21(2):444-9. PubMed ID: 16234293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
    Tincani E; Mannucci C; Casolari B; Turrini F; Crowther MA; Prisco D; Cenci AM; Bondi M
    Haematologica; 2006 Jul; 91(7):976-9. PubMed ID: 16757417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the low molecular weight heparin dalteparin in cats.
    Mischke R; Schmitt J; Wolken S; Böhm C; Wolf P; Kietzmann M
    Vet J; 2012 Jun; 192(3):299-303. PubMed ID: 21978598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
    Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
    Rodger MA; Ramsay T; MacKinnon M; Westphal M; Wells PS; McCormick B; Knoll G
    Am J Kidney Dis; 2012 Sep; 60(3):427-34. PubMed ID: 22480794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
    Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
    Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
    Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
    Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.